Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: Evidence for long-term efficacy

Clinical and Experimental Rheumatology

Volumn 32, Issue 4, 2014, Pages 490-494

  de Vita, Salvatore ^a   Quartuccio, Luca ^a   Salvin, Sara ^a   Picco, Luca ^a   Scott, Cathryn Anne ^a   Rupolo, Maurizio ^b   Fabris, Martina ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Belimumab; Cryoglobulinaemia; Lymphoma; Rituximab; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; COLCHICINE; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; IMMUNOGLOBULIN G; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIP BIOPSY; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; SKIN ULCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL, MARGINAL ZONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84904900825     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. TZIOUFAS AG, VOULGARELIS M: Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007: 21: 989-1010.
2. QUARTUCCIO L, ISOLA M, BALDINI C et al.: Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmunity 2013 Nov 11 [Epub ahead of print].
3. QUARTUCCIO L, FABRIS M, SALVIN S, MASET M, De MARCHI G, De VITA S: Controversies on rituximab therapy in Sjögren's syndrome-associated lymphoproliferation. Int J Rheumatol 2009; 2009: 424935.
4. LAVIE F, MICELI-RICHARD C, QUILLARD J, ROUX S, LECLERC P, MARIETTE X: Expression of BAFF (BlyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004; 202: 496-502.
5. QUARTUCCIO L, SALVIN S, FABRIS M et al.: BlyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52: 276-81.
6. GONG Q, OU Q, YE S et al.: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-26.
7. De VITA S, De MARCHI G, SACCO S, ZAJA F, SCOTT CA, FERRACCIOLI G: Treatment of B-cell disorders of MALT in Sjögren's syndrome with anti-CD20 monoclonal antibody. The VIIIth international symposium on Sjögren's syndrome, Kanazawa, Japan, May 2002; P8-2, page 51. [Abstract].
8. DASS S, BOWMAN SJ, VITAL EM et al.: Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
9. MEKINIAN A, RAVAUD P, LARROCHE C et al.; Club Rhumatismes et Iinflammation: Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry. Clin Exp Rheumatol 2012; 30: 208-12.
10. MOSCA M, van VOLLENHOVEN R: New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S82-5.
11. MARIETTE X, QUARTUCCIO L, SEROR S et al.: Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjögren's Syndrome. Ann Rheum Dis 2013 Dec 17 [Epub ahead of print].
12. De VITA S, SEROR R, QUARTUCCIO L et al.: Efficacy of belimumab on non-malignant parotid swelling and systemic manifestations of Sjögren's syndrome results of the BELISS study. Arthritis Rheum 2012; 64: S926.
13. De RE V, De VITA S, SANSONNO D et al.: Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology (Oxford) 2006; 45: 685-93.
14. De VITA S, QUARTUCCIO L, SALVIN S, CORAZZA L, ZABOTTI A, FABRIS M: Cryoglobulinaemia related to Sjögren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and aboratori tests after parotidectomy. Rheumatology (Oxford) 2012; 51: 627-33.
15. QUARTUCCIO L, FABRIS M, MORETTI M et al.: Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid b-cell lymphoma. Open Rheumatol J 2008; 2: 38-43.
16. ISHIYAMA K, TAKAMI A, OKUMURA H et al.: Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. Int J Hematol 2005; 81: 319-22.